Quarterly report pursuant to Section 13 or 15(d)

Accounts Payable and Accrued Expenses (Tables)

v3.24.3
Accounts Payable and Accrued Expenses (Tables)
9 Months Ended
Sep. 30, 2024
Accounts Payable and Accrued Expenses  
Schedule of Accounts Payable and Accrued Expenses

September 30, 

December 31, 

($ in thousands)

2024

    

2023

Accounts payable

$

8,759

$

6,322

Accrued research and development

561

4,118

Accrued compensation

984

2,838

Other (1)

1,757

739

Total accounts payable and accrued expenses

$

12,061

$

14,017

(1) Other includes approximately $1.3 million of accrued consideration for the uBriGene Asset Purchase Agreement, see Note 5.